Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study

Conclusion: 68Ga-OPS202 showed favorable biodistribution and imaging properties, with optimal tumor contrast between 1 and 2 h after injection. Dosimetry analysis revealed that the dose delivered by 68Ga-OPS202 to organs is similar to that delivered by other 68Ga-labeled sst analogs. Further evaluation of 68Ga-OPS202 for PET/CT imaging of NETs is therefore warranted.

Source: Journal of Nuclear Medicine - June 1, 2018 Category: Nuclear Medicine Authors: Nicolas, G. P., Beykan, S., Bouterfa, H., Kaufmann, J., Bauman, A., Lassmann, M., Reubi, J. C., Rivier, J. E. F., Maecke, H. R., Fani, M., Wild, D. Tags: Clinical Source Type: research